What are the GMP Requirements for Consultants?

Recommendation
17/18 September 2025
Building a Knowledge Framework in GMP
In FDA warning letters, the FDA sometimes advises the employment of a consultant in order to remedy the deficiencies addressed. But what are the requirements regarding such consultants from a GMP perspective?
The FDA's CGMP guidelines provide instructions on this in 21 CFR 211.34:
"Consultants advising on the manufacture, processing, packing, or holding of drug products shall have sufficient education, training, and experience, or any combination thereof, to advise on the subject for which they are retained. Records shall be maintained stating the name, address, and qualifications of any consultants and the type of service they provide."
Fortunately, the EU GMP Guideline Part I includes almost the same requirements in chapters 2.23 and 2.24:
- Consultants should have adaquate education, training and experience, or any combination thereof, to advise on the subject, for which they are retained.
- Records should be maintained stating the name, adress, qualification, and type of service providide by these consultants.
So far, so good. However, in a recent warning letter, the FDA explicitly points out that even if a consultant who meets the aforementioned requirements (21 CFR 211.34) is employed, the company itself is still responsible for GMP compliance.
The warning letter particularly and explicitly mentions the executive management as being responsible for dealing with all deviations and deficiencies in order to comply with CGMP.
Interestingly, the FDA recommends that the consultant should audit the company according to the 6-system audit system. This 6-system audit system was once intended as an inspection model for FDA inspections as described in the 2006 Quality Systems Approach to Pharmaceutical CGMP Regulations. To date, this model has not been widely adopted for FDA inspections. It is therefore all the more surprising that it is now recommended for clarification of GMP deficiencies.
You may find the warning letter mentioned above on the FDA website.
Related GMP News
10.09.2025The Use of Hoses in Pharmaceutical Production
10.09.2025Revision of EU-GMP Chapter 1 planned with Consultation Phase
10.09.2025Audit Trail Review by the QP / Dealing with a Lack of Justification
10.09.2025Why Human Error is not the End but the Beginning: Rethinking Deviation Management
03.09.2025Is QP Release possible after deviating In-Process Controls?